BUDGET IMPACT ANALYSIS- AN ACCEPTABLE PART OF VALUE ASSESSMENTS OR A DISCORDANT CONCEPT?
Author(s)
Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, USA; Dan Leonard, MA, National Pharmaceutical Council, Washington, USA; Peter J. Neumann, ScD, Tufts Medical Center, Boston, USA; Steven D. Pearson, MD, MSc, Institute for Clinical and Economic Review, Boston, USA; Matt Salo, BA, National Association of Medicaid Directors, Washington, USA
Presentation Documents
The ISPOR Budget Impact Analysis Good Practice II Task Force defines BIA as an estimation of “…the expected changes in expenditure of a healthcare system after the adoption of a new intervention.” The use of BIAs by payers in coverage and reimbursement decisions creates the potential to considerably impact patients and society. For example, does one disincentivize innovation in highly prevalent diseases or does one not inhibit giving treatments with greater clinical benefit a larger share of the available budget? Should BIAs be included in value assessments? If not, why not? Should cost effective treatments be viewed as investments and not part of annual budgeting? Join us as we host an ideological clash on the utility of BIAs in value assessments.
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Topic
Economic Evaluation, Health Technology Assessment